|
New Technology in Skin Permeation Enables Low Cost and Compact 3rd Generation
SonoPrep
FRANKLIN, Mass., Dec. 16 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that the SonoPrep technology and
applications in drug delivery and diagnosis will be presented at the 8th US -
Japan Symposium on Drug Delivery Systems. The latest developments and
breakthroughs in Sontras SonoPrep skin permeation technology will be
presented. The conference is held every two years and brings together
academic and industrial leaders from Japan and the United States to discuss
drug delivery breakthroughs.
Thomas Davison, Ph.D., President and CEO of Sontra, will be presenting the
capabilities and evolution of the SonoPrep technology at the opening plenary
session being held on Sunday, December 18, 2005 at the Westin Maui in Lahaina,
Hawaii. For more information:
http://web.mit.edu/langerlab/8thsymposium/index.html
"It is a privilege to be invited to participate in this exciting exchange
of ideas and opportunities in drug delivery," stated Dr. Davison. "More
significant to me personally is the honor that I have in presenting the
advances made in Sontras skin permeation technology, which is the product of
determination and brilliant scientific discovery by Sontras research and
development team."
Driven by the opportunity to expand the applications of SonoPrep, Sontra
engineers and scientists developed expanded capabilities in drug delivery that
will be incorporated into Sontras second generation SonoPrep instrument.
These advances include the combination of iontophoresis and a larger treatment
area, which will facilitate even faster onset and higher dose capabilities.
Looking toward the future and the requirements of self-administration of
transdermal drugs and continuous monitoring at home to manage diabetes, Sontra
engineers developed breakthrough technology that will be incorporated into the
third generation of SonoPrep skin permeation instruments that will have the
simplicity, size, portability and cost of an electric toothbrush. Dr. Davison
stated, "Reduced cost, compact size and simplicity are significant design
criteria for the diabetes management home glucose monitoring product and self-
administered transdermal drug regimens."
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science.
Sontras SonoPrep ultrasound-mediated skin permeation technology combined with
technical competencies in transdermal drug formulation, delivery systems and
biosensors is creating a new paradigm in transdermal drug delivery and
diagnosis. The SonoPrep technology is being developed for several billion
dollar market opportunities, including continuous glucose monitoring and the
transdermal delivery of large molecule drugs and vaccines. Sontra is
currently marketing the SonoPrep device and procedure tray for use with
topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
Investor Relations Contacts:
Sontra Medical Corporation
Sean Moran, Chief Financial Officer
508-530-0334
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected benefits and efficacy
of the SonoPrep device in connection with diagnostics, vaccine delivery,
glucose monitoring and transdermal drug delivery, the expected benefits,
features, market opportunities, distribution and market acceptance of the
SonoPrep device and technology, the expected size of the markets for the
SonoPrep device and technology, Sontras expected ability to commercialize
additional products, and Sontras business, research and marketing strategies
and product development plans. Statements that are not historical facts,
including statements about our beliefs and expectations, are forward-looking
statements. Such statements are based on our current expectations and are
subject to a number of factors and uncertainties, which could cause actual
results to differ materially from those described in the forward-looking
statements. The following important factors and uncertainties, among others,
could cause actual results to differ materially from those described in these
forward-looking statements: our technology is new and we may experience
adverse results in research collaborations, product development, clinical
trials, product evaluations, commercialization efforts, product distribution
and market acceptance; markets for our products may develop slower than
expected, or not at all; our sales cycle is lengthy and we are still
developing sales and marketing strategies which may or may not prove
effective; the SonoPrep device may not prove effective in connection with
diagnostics, vaccine delivery, glucose monitoring and/or transdermal drug
delivery; Bayer has retained co-exclusive rights to the hospital ICU market
and may compete with Sontra in such market; we may experience difficulties or
delays in obtaining regulatory approvals to market products resulting from
development efforts or difficulties or delays associated with sources of
regulatory-approved transdermal drugs and vaccines; failure to obtain and
maintain patent protection for discoveries or commercial limitations imposed
by patents owned or controlled by third parties would have an adverse effect
on us; we depend upon strategic partners and third-party distributors to
develop, commercialize, market and sell products based on our work; and we
require substantial additional funding to conduct research and development and
to expand commercialization, distribution and marketing activities. For
detailed information about factors that could cause actual results to differ
materially from those described in the forward-looking statements, please
refer to Sontras filings with the Securities and Exchange Commission,
including Sontras most recent Quarterly Report on Form 10-QSB. Forward-
looking statements represent managements current expectations and are
inherently uncertain. We do not undertake any obligation to update forward-
looking statements made by us.
|
|
